• Accueil >
  • Publications >
  • First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours

First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours

1 nov. 2017European Journal of Cancer

DOI : 10.1016/j.ejca.2017.09.009

Auteurs

Patrick Schöffski, Jean-Pierre Delord, Etienne Brain, Jacques Robert, Herlinde Dumez, Jamal Gasmi, André Trouet